Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
Silence breaks down phase 1 data on blood disorder prospect
The polycythemia vera data provide an early look at how the siRNA prospect may match up to rivals from Incyte and Takeda.
Nick Paul Taylor
Jun 27, 2024 9:40am
Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2
Mar 13, 2024 8:54am
Boehringer bets $2B in biobucks on siRNA treatments for MASH
Jan 3, 2024 6:00am
ADARx preps 3rd clinical program and mulls IPO
Oct 3, 2023 10:55am
RNA biotech ADARx hauls in healthy $200M series C
Aug 9, 2023 10:17am
Aligos culls another hep B asset over inconclusive efficacy data
Aug 4, 2023 7:27am